Compare AXGN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXGN | AUPH |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | Canada |
| Employees | 452 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | 1999 |
| Metric | AXGN | AUPH |
|---|---|---|
| Price | $30.50 | $15.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $33.67 | $17.25 |
| AVG Volume (30 Days) | 922.8K | ★ 1.1M |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | $214,709,000.00 | ★ $265,808,000.00 |
| Revenue This Year | $21.60 | $21.76 |
| Revenue Next Year | $15.83 | $16.45 |
| P/E Ratio | ★ N/A | $28.99 |
| Revenue Growth | 18.72 | ★ 20.62 |
| 52 Week Low | $9.22 | $6.55 |
| 52 Week High | $34.24 | $16.54 |
| Indicator | AXGN | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 51.59 | 42.04 |
| Support Level | $32.03 | $15.64 |
| Resistance Level | $33.84 | $15.98 |
| Average True Range (ATR) | 1.39 | 0.39 |
| MACD | -0.32 | -0.13 |
| Stochastic Oscillator | 32.41 | 8.50 |
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.